



UCB News

Disposals of own shares

Brussels (Belgium), 3 January 2022 – 20:00 (CET) – regulated information

Disposal of own shares

In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

Date of transaction	Time	LTI Plan	Number of disposed UCB shares	Price
27 December 2021	09:11:59	Stock Option Plan 2012	400	€ 32,36
27 December 2021	14:25:01	Stock Option Plan 2012	200	€ 32,36

In addition to these exercises, on 30 December 2021, in accordance with the vesting rules under its 2017 and 2018 LTI plans, UCB SA/NV has delivered for free a total of 5 021 UCB shares OTC to 2 members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 30 December 2021 was € 101,05.

This press release is available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte
Investor Relations, UCB

T +32 2 559 94 14,
antje.witte@ucb.com

Corporate Communications

Laurent Schots
Media Relations, UCB

T+32.2.559.92.64
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 400 people in nearly 40 countries, the company generated revenue of € 5.3 billion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: [@UCB_news](https://twitter.com/UCB_news)